Vaxxinity’s “Groundbreaking” Exploratory Data in Parkinson’s Disease Published in Nature Medicine

Vaxxinity, Inc (Nasdaq: VAXX) topped the PRISM Global Health Index on Thursday with a 14.92% rise in its share price. The market reacted favorably to the company’s announcement that groundbreaking exploratory data from its Phase 1 clinical trial of UB-312 in patients with Parkinson’s disease has been published in Nature Medicine. UB-312 is an active immunotherapy medicine (AIM) designed to slow or stop Parkinson’s progression by addressing the root cause of the disease.

Vaxxinity’s UB-312 is the first Parkinson’s disease candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. UB-312-induced antibodies significantly decreased levels of aggregated α-synuclein (αSyn), a key pathology in Parkinson’s disease. This suggests that UB-312 can help to eliminate the buildup of harmful, toxic forms of the protein αSyn in the brain.

Lou Reese, Co-Founder and Executive Chairman of Vaxxinity, said, “The publication of this data in Nature Medicine immortalizes the profound impact of UB-312, leading the charge against the very core of Parkinson’s. It sparks a beacon of hope and anticipation for a future where Parkinson’s no longer determines the trajectory of lives. This is more than just a scientific breakthrough; it’s a battle cry for change, declaring that the status quo in Parkinson’s care is no longer acceptable.”

The exploratory biomarker and target engagement research portion of the trial was funded by The Michael J. Fox Foundation (MJFF), and marked a two-year collaborative project between Vaxxinity, the Mayo Clinic, and UTHealth Houston to analyze cerebrospinal fluid collected from patients.

Parkinson’s disease is a progressive neurological disorder that affects approximately 10 million people worldwide.

About Vaxxinity

Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of medicines known as AIMs (active immunotherapy medicines) with the goal of disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary AIM technology platform has enabled the innovation of novel synthetic peptide immunotherapy candidates designed to bring the efficiency of active immunotherapies to the treatment of chronic diseases, including Alzheimer’s disease, Parkinson’s disease, migraine, and hypercholesterolemia. The technology is also implemented as part of a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health. For more information about Vaxxinity, Inc., visit and follow us on social media @vaxxinity.

Share This Article


About the Author

Vaxxinity’s “Groundbreaking” Exploratory Data in Parkinson’s Disease Published in Nature Medicine

Catie Corcoran

Biotech Editor